Contact us

877-469-1TRM
424-208-8866

STUDY INFORMATION

We know at TRM, patient participation in clinical trials is key to one day finding a cure for cancer. To enable physicians wanting to refer patients to a study or a patient seeking new or additional treatment options, we have listed all the clinical trials being conducted throughout our network of sites. Not all sites will be participating in all clinical trials, so please contact us for additional details on how to refer a patient or participate.

The majority of studies listed are open and accruing and are actively seeking patients for participation, however, there will be studies listed as closed to accrual when a study has just recently closed. Summary information about the clinical trial is provided, along with a link to the CliniicalTrials.gov website for more detailed information.

Clinical Trials By Disease

Breast
Title Patient Population Investigational Product(s) Phase Status
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer details » Metastatic Breast Cancer Overexpressing HER-2 KW-2450 I/II Closed
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy details » High Risk Early Breast Cancer (D-Care) Denosumab II Closed
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer details » Her2 Negative Breast Cancer Patients MM-121 (SAR256212) and Exemestane Phase II Closed
NBRST: Prospective Neo-adjuvant REGISTRY Trial details » Breast Cancer N/A N/A Open and Accruing
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine or Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (tnAcity) details » Triple Negative Metastatic Breast Cancer Patients nab-Paclitaxel II/III Temporarily Closed to Accural
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients details » High Risk Stage II, III or IV Breast Cancer HM10460A II Closed to Accrual
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer details » Advanced/Metastatic HER2-Positive Breast Cancer MM-302 II Open and Accruing
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC) details » Metastatic gpNMB Over-expressing Triple Negative Breast Cancer CDX-011 II Open and Accruing
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) details » Advanced, Metastatic Breast Cancer LEE011 II Open and Accruing
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) details » HR+/HER2-Negative Metastatic Breast Cancer PD-0332991 (Palbocicilib) III Closed to Accrual
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) details » HR+/HER2-Negative Metastatic Breast Cancer PD-0332991 (Palbocicilib) III Closed to Accrual
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA) details » HER-2 Positive Breast Cancer Margetuximab III Open and Accruing
Colon
Title Patient Population Investigational Product(s) Phase Status
FOLFOX Plus SIR-Spheres Microspheres Versus FOLFOX Alone in Patients with Liver Mets from Primary Coloreactal Cancer details » Primary Colorectal Carcinoma with Non-Resectable Liver Metastases Sir-Spheres ® III Closed
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma details » Colorectal Cancer GS-6624 II Closed
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer details » Colorectal Cancer RO5083945 II Closed
A Study in Second Line Metastatic Colorectal Cancer details » Colorectal Cancer Ramucirumab III Closed
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE) details » Metastatic Colorectal Cancer – Third Line TAS-102 III Closed to Accrual
Gastrointestinal
Title Patient Population Investigational Product(s) Phase Status
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial DIGEST details » Metastatic Diffuse Gastric Cancer S-1 III Closed
Gynecologic
Title Patient Population Investigational Product(s) Phase Status
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/Refractory Advanced Ovarian Cancers details » Ovarian MM-121 II Closed to Accrual
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers details » Gynecologic and Breast Cancer MM-121 I Closed to Accrual
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Patients With Ovarian Cancer details » Advanced Ovarian Cancer Doxorubicin HCL Liposome I Closed
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer details »
Relapsed Epithelial Ovarian
Relapsed Primary Peritoneal
Relapsed Fallopian Tube
TL32711 (Birinapant) Ib Closed to Accrual
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL) details » Ovarian Lurbinectedin (PM01183) III Open and Accruing
Head and Neck
Title Patient Population Investigational Product(s) Phase Status
Efficacy and Safety Study of Clonidine Lauriad™ to Treat Oral Mucositis details » Head and Neck Cancer Patients Receiving Chemo-Radiation Clonidine Lauriad II Open and Accruing
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity (IT-MATTERS) details » Squamous Cell Carcinoma of the Oral Cavity Multikine III Open and Accruing
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer details » Oral Mucositis Cobiprostone II Open and Accruing
Leukemia and Blood Disorders
Title Patient Population Investigational Product(s) Phase Status
Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia Subjects ≥ 65 details » Acute Myeloid Leukemia, Acute Myelogenous Leukemia Lenalidomide II Open and Accruing
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients details » Myelodysplastic Syndrome Vidaza I Closed
Study to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects details » Older Subjects w/Newly Diagnosed Acute Myeloid Leukemia Lenalidomide (Revlimid) II Open and Accruing
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy details » Myelodysplastic Syndrome TL32711 (Birinapant) Ib/2a Closed to Accrual
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma details » Multiple Myeloma Daratumumab III Open and Accruing
Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL details » Chronic Lympocytic Leukemia ACP-196 III Open and Accruing
Previous Study | Return to List | Next Study Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL details » MDS OR CML Birinapant II Open and Accruing
A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation details » Multiple Myeloma Ixazomib III Open and Accruing
Lung
Title Patient Population Investigational Product(s) Phase Status
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Lung Cancer details » Non-Small Cell Lung Cancer U3-1287 (AMG 888) IB/II Closed
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung details » Adenocarcinoma of the Lung Farletuzumab II Closed
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed details » Malignant Pleural Mesothelioma NGR-hTNF III Closed
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy details » Non Small Cell Lung Cancer Ramucirumab III Closed
An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After Firs details » Refractory or Recurrent NSCLC Bevacizumab [Avastin] IIIb Open and Accruing
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) details » 2nd or 3rd Line NSCLC U3-1287 (AMG 888) III Open and Accruing
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer (aboundsqm) details » Squamous Cell Carcinoma, Non-Small-Cell Lung nab-Paclitaxel III Open and Accruing
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE) details » Non-Small-Cell Lung Cancer Stage IIIB Bavituximab III Open and Accruing
Study Evaluating the Efficacy, Safety and Pharmacokinetics in Patient With T790M-positive Non-small Cell Lung Cancer (NSCLC) details » NSCLC HM61713 II Open and Accruing
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer details » NSCLC CC-486 and Pembrolizumab II Open and Accruing
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) details » NSCLC AZD9291 III Open and Accruing
AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3) details » NSCLC AZD9291 III Open and Accruing
Lymphoma
Title Patient Population Investigational Product(s) Phase Status
Safety Study of Darinaparsin in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma details » Lymphoma scheduled for CHOP (likely Peripheral T-Cell Lymphomas) Darinaparsin I Closed
Rituximab Plus Lenalidomide Combination Therapy for Patients With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma (AUGMENT) details » Relapsed/Refractory Follicular Lymphoma Lenalidomide III Open and Accruing
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity) details » Triple Negative Metastatic Breast Cancer nab-Paclitaxel II/III Open and Accruing
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin’s Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT) details » Non-Hodgkin’s Lymphoma Lenalidomide (Revlimid) III Open and Accruing
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) details » Refractory Indolent Non-Hodgkin Lymphoma IPI-145 II Open and Accruing
Non Disease-specific
Title Patient Population Investigational Product(s) Phase Status
Biospecimen Collection for Use for Future Scientific Research details » All Cancers N/A IV Open and Accruing
NP2 Enkephalin For Treatment of Intractable Cancer Pain details » All Cancers NP2 II Closed
Pancreatic
Title Patient Population Investigational Product(s) Phase Status
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma details » Pancreatic Cancer GS-6624 II Closed to Accrual
Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer (NAPOLI 1) details » Metastatic Pancreatic Cancer MM-398 III Closed to Accrual
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT®-1) details » Metastatic Pancreatic Cancer 90Y-Clivatuzumab Tetraxetan III Opening August 2014
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) details » Metastatic Pancreatic Adenocarcinoma JAK Inhibitor III Open and Accruing
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer details » Pancreatic Glufosfamide III Open and Accruing